WO2000035472A2 - Cytokine combination therapy - Google Patents
Cytokine combination therapy Download PDFInfo
- Publication number
- WO2000035472A2 WO2000035472A2 PCT/IB1999/002001 IB9902001W WO0035472A2 WO 2000035472 A2 WO2000035472 A2 WO 2000035472A2 IB 9902001 W IB9902001 W IB 9902001W WO 0035472 A2 WO0035472 A2 WO 0035472A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cytokine
- agonist
- antagonist
- compound
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Definitions
- This invention relates to methods of treatment of patients for enhancing immune response, treating viral infection (including retroviral infection), bacterial infection, fungal infection, parasitic infection and/or infectious protein units in a patient in need of such treatment, or minimizing the likelihood of such infection and/or reducing the potential future adversity of such infection in a patient.
- the invention further relates to methods of providing immunosuppressive or immunoregulatory effects in a patient.
- the invention further relates to the use of compounds in the manufacture of medicaments for use in treating a variety conditions, as well as compositions and kits containing the active materials according to the present invention.
- HIV- I Human Immunodeficiency Virus Type I
- AIDS Acquired Immune Deficiency Syndrome
- AIDS is characterized as a profound breakdown in host's cellular and humoral immunity and increased susceptibility to a wide range of opportunistic infections.
- One of the consequences of this immune dysfunction is a marked depletion in absolute CD4+ cells in HIV-infected individuals.
- the HIV protease enzyme is responsible for post translational processing of gag and gag-pol polyprotein precursors into their functional products. This aspartyl type protease has been identified as a potential target for antiretroviral therapy, as inhibition of the enzyme results in the production of immature non-infectious virions and subsequent interruption of viral spread.
- methods of treatment of a patient for enhancing immune response comprising administering to the patient (1) at least one anti-viral agent and (2) at least one agonist and/or at least one antagonist to a Th 2 cytokine.
- methods of treating viral infection including retroviral infection
- bacterial infection including retroviral infection
- fungal infection including retroviral infection
- parasitic infection including retroviral infection
- infectious protein units in a patient
- administering comprising administering to the patient (1) at least one anti-viral agent and (2) at least one agonist and/or at least one antagonist to a Th 2 cytokine.
- Another aspect of the present invention relates to methods of providing immunosuppression or immunoregulatory effect a in patient, comprising administering to the patient (1) at least one anti-viral agent and (2) at least one agonist and/or at least one antagonist to a Th 2 cytokine.
- the present invention provides methods of treatment of persons and animals with indications of immuno-deficiency, wherein the said indication is resultant from viral and/or retroviral, bacterial, fungal or parasitic infection and/or plus infectious protein units.
- Th 2 cytokines in combination with anti-viral agents or immune enhancing agents.
- the agonist or antagonist is a receptor to lnterleukin-4 (or mutein receptor) which is administered in combination with an anti-viral agent.
- Preferred anti-viral/immune-enhancing agents include (a) "compounds of Formula I" (defined below), and metabolites, analogs and precursors thereof, and pharmaceutically acceptable salts of any such compounds, metabolites, analogs and precursors, (b) protease inhibitors, and (c) reverse transcriptase inhibitors. Additionally herein is described a method of enhancing viral replication as a means of exposing latent infection by the administration of an agonist or antagonist to a Th 2 cytokine.
- lnterleukin-4 e.g., preferably a receptor to IL-4 (lnterleukin-4)
- lnterleukin-4 a receptor to IL-4
- a novel treatment regimen which enhances viral replication, thus allowing more effective protease enzyme inhibition wherein the viral enhancing pharmaceutical agent is part of a combination therapy with protease inhibitors and/or reverse transcriptase inhibitors.
- the present invention further relates to methods of reducing proviral DHA in patients, and/or facilitating transport into immune cells.
- the present invention stems from the novel discovery that peptide/glycopeptide sequences exhibited as components of immature non-infectious virions coat proteins or glycoproteins act in a deleterious manner to human and animal biological functions by binding specifically to the receptor molecules of certain Th 2 cytokines.
- the presence of these peptides, polypeptides/glycopeptide sequences which facilitate binding to receptor molecules to Th 2 cytokines is the essential factor, which allows these classes of virions both infectious and non-infectious to inhibit improved immune response.
- This discovery opens new avenues to treatment and/or prevention by inoculation or therapy of immunosuppressive disorders and/or viral, certain bacterial and/or mycoplasma infections.
- hlL-4 is produced by T-cells and acts as a growth factor for pre-activated B-cells and T-cells. It acts on enriched B- cell populations to produce IgE and on purified B-cells to secrete IgG and IgM. It enhances the generation of cytotoxic T-cells but inhibits the IL-2 (lnterleukin-2) dependent generation of lymphocyte-activated killer cells. hlL-4 shows numerous growth and differentiation promoting effects on other hemopoietic lineages.
- IL-4 elicits its biological activities by binding to specific receptors on the cell surface of IL-4 responsive cells. Binding of IL-4 to its receptor causes rapid receptor internalisation followed by up-regulation of IL-4 receptor expression in the case of a human B lymphoma, human tonsillar B-cells, and mouse T- and B-cells.
- This invention further relates to methods of treatment of persons and animals with indications of immuno-deficiency, wherein the said indication is resultant from viral and/or retroviral infection and/or infectious protein units originating from bacterial, fungal or parasitic sources.
- a combination therapy in which (1) one or more anti-viral agent, and (2) recombinant receptor to IL-4, are administered (individually or in any combinations) to a patient to bring about a reduction in the level of proviral DNA (i.e., latent viral cells in the patient's circulation).
- proviral DNA i.e., latent viral cells in the patient's circulation.
- a combination therapy in which (1) one or more anti-viral agent, (2) recombinant receptor to IL-4, and (3) IL-4 are administered (individually or in any combinations) to a patient to bring about a reduction in the level of proviral DNA.
- IL-4 is administered in addition to recombinant receptor to IL-4, there is often obtained a further sustainment of reduction in proviral DNA, because this treatment avoids depletion of the patient's IL-4 resulting from the administration of recombinant receptor to IL-4. Furthermore, binding of recombinant receptor to IL-4 with IL-4 makes it acceptable into immune cells by facilitating transport into the immune cells.
- the acquired immunodeficiency syndrome is characterised by a profound immune dysfunction and opportunistic infections.
- the immunologic abnormalities include not only the T-helper/inducer lymphocyte subset but also most if not all the major cellular components of the immune system including B lymphocytes, monocytes/macrophages, natural killer cells (NK), and others. Therefore, it is reasonable to expect that in addition to a selective depression of CD4 helper lymphocytes, there exists additional immunoregulatory mechanisms involved in the observed immunodepression of HIV.
- Abnormalities in NK (Natural Killer) cell activity have been reported in AIDS patients in spite of an apparently normal number of circulating NK cells.
- IL-l ⁇ Interleukin 1 ⁇
- IL-2 lnterleukin-2
- IFN vj Interferon y
- the system is inhibited by lnterleukin-4 (IL-4) and also by prostaglandin E 2 (PGE 2 ) and histamine, which are released when the immune system is activated.
- IL-4 also presents in the transmembrane amino acid sequences of certain viruses including HIV which allow the full vigilance of the immune system to be deflected to a Th 2 system allowing infection to gain a hold and avoid complete viral clearance.
- HIV envelope glycoprotein is synthesised as a polyprotein precursor of 160 kDa
- gp 160 is subsequently cleaved into an amino terminus subunit, gp 120, and a carboxy terminus transmembrane subunit, gp41.
- Lymphocytes from AIDS patients have been reported to secrete a protein with immunosuppressive properties.
- Mitogen- and antigen-driven blastogenic responses have been shown to be inhibited by purified HIV preparations.
- the immunosuppressive properties including the inhibition of normal human NK cell activity, of the FeL V transmembrane glycoprotein P15E and the suppression of mitogen- and alloantigen-induced lymphocyte blastogenesis by HIV synthetic peptides 735-752 and 846-860 corresponding to sequences within the HIV transmembrane gp41. Both these transmembrane HIV peptides were found to have a significant inhibitory effect on NK cell activity, even at doses as low as 0.1 ⁇ g/ml.
- One of the mechanisms by which the immune system normally regulates itself includes the production of proteins called cytokines.
- lymphokines are cytokines produced by T-cells and some B-cells, and monokines are cytokines produced by monocytes. Cytokines, which may be glycosylated, mediate numerous immune responses.
- IL-4 is a cytokine capable of stimulating production of antibody producing B-cells and which also promotes growth of killer T-cells or cytotoxic T-cells. Additionally, it can inhibit the activity of T-helper cells type 1 (Th1). This in turn may inhibit production of more B-cells or antibody production by more B-cells.
- Th1 T-helper cells type 1
- Compounds of the invention include muteins human and murine IL-4s, and nucleic acids which are effectively homologous to disclosed cDNAs, and/or which are capable of coding for mammalian p IL-4s muteins as per Lee et al
- agonist or antagonist to lnterleukin-4 as part of a combination therapy for use in the prophylaxis and therapy of a viral infection, or a complication or consequence thereof.
- the viral agent may be any virus, a specific preferred example being the Human Immunodeficiency Virus.
- Preferred anti-viral agents include compounds of Formula I:
- X and Y are each independently selected from hydroxy, hydrogen, lower alkyl, CO 2 R 33 (i.e., - O - C(O)-R 33 or - C(O) - O - R 33 ), halogen (such as Br, Cl, F or I), oxygen (double-bonded to the 16-position or 17-position carbon atom), and steroid molecule residue (residue B), wherein R 33 is a straight or branched chain alkyl radical of 1 to 14 carbon atoms, said steroid molecule residue (residue B) having a structure corresponding to Formula I (with one hydrogen atom removed therefrom) and in which the moieties on residue B corresponding to positions X and Y (if present) are independently selected from halogen (e.g., Br, Cl, F or I), hydrogen, hydroxy, and CO 2 R 34 , wherein R 34 is a straight or branched chain alkyl radical of 1 to 14 carbon atoms;
- R T - R 16 and R 18 - R 31 are each independently selected from hydrogen, halogen (such as Br, Cl, F or I), hydroxy, C, - C 6 alkoxy, C, - C 6 alkyl and -S-CN;
- R 17 is selected from hydrogen, hydroxy, halogen (such as Br, Cl, F or I), oxygen
- R 32 is selected from:
- R 35 and R 36 are each independently selected from straight or branched chain alkyl radical of 1 to 14 carbon atoms
- R 37 and R 3 ⁇ are each independently selected from straight or branched chain alkyl radical of 1 to 14 carbon atoms or a glucuronide group having the formula
- R M and R ⁇ are each independently selected from straight or branched chain alkyl radical of 1 to 14 carbon atoms
- R 37 and R 38 are each independently selected from straight or branched chain alkyl radical of 1 to 14 carbon atoms or a glucuronide group having the formula
- R 39 and R 40 are each independently selected from straight or branched chain alkyl radical of 1 to 14 carbon atoms
- R 41 and R 42 are each independently selected from straight or branched chain alkyl radical of 1 to 14 carbon atoms or a glucuronide group having the formula
- the anti-viral agent is selected from among compound having the following formula 1 - 25 (and precursors, metabolites and analogs thereof):
- R 43 is a hydrogen atom or bromine atom
- R ⁇ is:
- R 45 and R 46 are each independently selected from straight or branched chain alkyl radical of 1 to 14 carbon atoms
- R 47 and R 4 ⁇ are each independently selected from straight or branched chain alkyl radical of 1 to 14 carbon atoms or a glucuronide group having the formula
- R 43 and R 44 are each hydrogen.
- An especially preferred compound is dehydroepiandrosterone (DHEA) wherein R 43 and R 44 are each hydrogen and the double bond is present.
- the compound is epiandrosterone wherein R 43 and R 44 are each hydrogen and the double bond is absent.
- This unsaturated 5-position steroid can also be prepared as an anti-viral agent wherein the R 43 position is occupied by any of the following halogens (bromine, chlorine, fluorine, iodine).
- the compuond is 16 ⁇ -bromoepiandrosterone, wherein R 43 is Br, R 44 is H and the double bond is absent.
- the compound is according to formula I - 25, wherein R 43 is Br, R 44 is H and the double bond is not present (i.e., where the dotted line is shown in formula I - 25, there is a single bond).
- Other preferred compounds are dehydroepiandrosterone sulphate, wherein R 43 is H, R 44 is SO 2 -OM and M is as hereinbefore defined and the double bond is present, and 5 ⁇ -androstan-3 ⁇ -ol-17-one.
- the compound of Formula 1 may also be dehydroepiandrosterone sulphatides, phosphatides, or glucuronide wherein a hydrogen atom is attached to the carbon atom at the 16-position, and R, 7 is a sulphatide, phosphatide, or glucuronide group as hereinabove defined, and the double bond between the carbon atoms at the 5-position and the 6-position is present.
- the compounds may be DHEA conjugates such as hexyl sulfate, dodecyl sulfate, octadecyl sulfate, octadecanoylglycol sulfate, O-dihexadecylglycerol sulfate, hexadecane sulfonate, dioctadecanoylglycerol phosphate, or O-hexadecylglycerol phosphate.
- DHEA conjugates such as hexyl sulfate, dodecyl sulfate, octadecyl sulfate, octadecanoylglycol sulfate, O-dihexadecylglycerol sulfate, hexadecane sulfonate, dioctadecanoylglycerol phosphat
- the compounds of Formula 1 can exist in a polymorph form.
- Other preferred anti-viral agents include protease inhibitors.
- Protease inhibitors are drugs that resemble pieces of the protein chain that protease normally cuts. By “gumming up” the protease “scissors,” HIV protease inhibitors prevent protease from cutting long chains of proteins and enzymes into the shorter pieces that HIV needs to make new copies of itself. New copies of HIV are still made and still push through the wall of the infected cell even if the long chains are not cut up into the correct smaller pieces. But these new copies of HIV are “defective", in that they cannot go on to infect other cells.
- protease inhibitors can greatly reduce the number of new, infectious copies of HIV made inside cells. If protease inhibitors succeed in making most new HIV viruses defective, HIV infection would not spread inside the body as quickly as it does now.
- the European name for protease inhibitor is proteinase inhibitor. A protease inhibitor alone will generally not get rid of HIV in an infected person's body. Even though these drugs can reduce the amount of virus, more virus can remain elsewhere in the body. Because some infected cells are "dormant" or "latently infected” - meaning they are already infected but still waiting to make new virus - many researchers doubt that any one drug can remove all the virus in an infected person, believing that some virus will stay in the body in latently infected cells.
- protease inhibitors differ from the other anti-HIV drugs used now are in their target and in their strength. These other drugs are called reverse transcriptase inhibitors because they disturb the job of an HIV enzyme called reverse transcriptase.
- Reverse transcriptase is the enzyme HIV uses to change its chemical (or genetic) message into a form that can easily be inserted inside the nucleus of the infected cell.
- This step in the HIV replication process happens soon after HIV infects a cell - much earlier than the step in which protease inhibitors are involved. Because protease inhibitors and reverse transcriptase inhibitors work at two separate steps in the HIV replication process, some studies are testing the use of drugs from both groups at the same time to treat HIV infection.
- Protease inhibitors also differ from reverse transcriptase inhibitors in their
- HIV can become resistant to two or more drugs at the same time. When it does, HIV is said to be cross-resistant to those drugs.
- Other preferred anti-viral agents include reverse transcriptase inhibitors. In the United States, physicians may prescribe five reverse transcriptase inhibitors. The common names of these drugs are: AZT (Retrovir, zidovudine) ddl (Videx, didanosine)
- compositions which include one or more lnterleukin-4 receptor.
- preferred embodiments of the present invention relate to a combination therapy for the treatment of viral infection containing (a) an lnterleukin-4 receptor in combination with (b) an antiviral agent.
- lnterleukin-4 IL-4, also known as B-cell stimulating factor, or BSF-1 was originally characterised by its ability to stimulate the proliferation of B-cells in response to low concentrations of antibodies directed to surface immunoglobulin. More recently,
- IL-4 has been shown to possess a far broader spectrum of biological activities, including growth co-stimulation of T-cells, mast cells, granulocytes, megakaryocytes, and erythrocytes.
- IL-4 stimulates the proliferation of several IL-2 and IL-3 (lnterleukin-3) dependent cell lines, induces the expression of class II major histocompatibility complex molecules on resting B-cells, and enhances the secretion of IgE and lgG1 isotypes by stimulated B-cells.
- IL-2 and IL-3 laminocompatibility complex molecules
- Both murine and human IL-4 have been definitively characterised by recombinant DNA technology and by purification to homogeneity of the natural murine protein (Yokota et al., Proc. Natl. Acad. Sci. USA 83:5894, 1986; Norma et al., Nature 319:640, 1986; and Grabstein et al., J.
- IL-4 The biological activities of IL-4 are mediated by specific cell surface receptors for IL-4 which are expressed on primary cells and in vitro cell lines of mammalian origin. IL-4 binds to the receptor, which then transduces a biological signal to various immune effector cells.
- Purified IL-4 receptor (IL-4R) compositions will therefore be useful in diagnostic assays for IL-4 or IL-4 receptor, and in raising antibodies to IL-4 receptor for use in diagnosis or therapy.
- purified IL-4 receptor compositions may be used directly in therapy to bind or scavenge IL-4, providing a means for regulating the biological activities of this cytokine.
- IL-4 receptor or IL-4R refer to proteins which bind lnterleukin-4 (IL-4) molecules and, in their native configuration as intact human plasma membrane proteins, play a role in transducing the biological signal provided by IL-4 to
- Intact receptor proteins generally include an extracellular region which binds to a ligand, a hydrophobic transmembrane region which causes the protein to be immobilised within the plasma membrane lipid bilayer, and a cytoplasmic or intracellular region which interacts with cytoplasmic proteins and/or chemicals to deliver a biological signal to effector cells via a cascade of chemical reactions within the cytoplasm of the cell.
- the hydrophobic transmembrane region and a highly charged sequence of amino acids in the cytoplasmic region immediately following the transmembrane region cooperatively function to halt transport of the IL-4 receptor across the plasma membrane.
- IL-4 receptors are proteins having amino acid sequences which are substantially similar to the native mammalian lnterleukin-4 receptor amino acid sequences disclosed in Fig. 1 (SEQ ID NO. 1) (i.e., Figs. 1A, 1B, 1C), and Fig. 2 (SEQ ID NO. 2) (i.e., Figs.
- IL-4 lnterleukin-4
- the native human IL-4 receptor molecule has an apparent molecular weight by SDS-PAGE of about 140 kilodaltons (kDa).
- the native murine IL-4 receptor molecule has an apparent molecular weight by SDS-PAGE of about 140 kilodaltons (kDa).
- IL-4 receptor or “IL-4R” include, but are not limited to, soluble IL-4 receptors, as defined below.
- Specific IL-4 receptor polypeptides are designated herein by parenthetically indicating the amino acid sequence numbers, followed by any additional amino acid sequences.
- mature means a protein expressed in a form lacking a leader sequence as may be present in full-length transcripts of a native gene.
- Various bioequivalent protein and amino acid analogs are described in the detailed description of the invention.
- Substantially similar IL-4 receptors include those whose amino acid or nucleic acid sequences vary from the native sequences by one or more substitutions, deletions, or additions, the net effect of which is to retain biological activity of the IL-4R protein.
- nucleic acid subunits and analogs are "substantially similar" to the specific
- DNA sequences disclosed herein if: (a) the DNA sequence is derived from the coding region of a native mammalian IL-4R gene; (b) the DNA sequence is capable of
- nucleic acid sequences In defining nucleic acid sequences, all subject nucleic acid sequences capable of encoding substantially similar amino acid sequences are considered substantially similar to a reference nucleic acid sequence. Percent similarity may be determined, for example, by comparing sequence information using the GAP computer program, version 6.0, available from the University of Wisconsin Genetics Computer Group (UWGCG). The GAP program utilises the alignment method of Needleman and Wunsch (J. Mol. Biol. 48: 443, 1970), as revised by Smith and Waterman (Adv. Appl Math.2:482, 1981). Briefly, the GAP program defines similarity as the number of aligned symbols (i.e., nucleotides or amino acids) which are similar, divided by the total number of symbols in the shorter of the two sequences.
- the preferred default parameters for the GAP program include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non-identies) for nucleotides) for nucleotides, and the weighted comparison matrix of Gribskov and Burgess, Nucl. Acids Res. 14:6745, 1986, as described by Schwartz and Dayhoff, ed., Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, pp. 353-358, 1979; (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps.
- soluble IL-4 receptor or “slL4-R” as used in the context of the present invention refers to a protein, or a substantially equivalent analog, having an amino acid sequence corresponding to the extracellular region of native IL-4 receptors, for example, polypeptides having the amino acid sequences substantially equivalent to the sequences of amino acids 1-208 of Fig. 1A (part of SEQ ID NO. 1), amino acids 1-207 of Fig. 2A (part of SEQ ID NO. 2).
- Equivalent slL-4Rs include polypeptides which vary
- slL-4R proteins are devoid of a transmembrane region, they are secreted from the host cell in which they are produced. When administered in therapeutic formulations, slL-4R proteins circulate in the body and bind to circulating IL-4 molecules, preventing interaction of IL-4 with natural IL-4 receptors and inhibiting transduction of IL-4 mediated biological signals, such as immune or inflammatory responses.
- the ability of a polypeptide to inhibit IL-4 signal transduction can be determined by transfecting cells with recombinant IL-4 receptor DNAs to obtain recombinant receptor expression. The cells are then contacted with IL-4 and the resulting metabolic effects examined. If an effect results which is attributable to the action of the ligand, then the recombinant receptor has signal transducing activity. Exemplary procedures for determining whether a polypeptide has signal transducing activity are disclosed by Idzerda et al., J. Exp. Med., March 1990 in press, Curtis et al., Proc. Natl. Acad. Sci. USA 86: 3045 (1989), Prywes et al., EMBO J.
- any one of the in vivo or in vitro assays described in Examples 1-10 can be utilised to determine whether a soluble IL-4R inhibits transduction of a specific IL-4 mediated biological signal.
- the cloning, sequencing and expression of full-length and soluble forms of the receptor for murine IL-4 have recently been described by Mosley et al., Cell 59:335, 1989.
- Recombinant means that a protein is derived from recombinant (e.g., microbial or mammalian) expression systems.
- Microbial refers to recombinant proteins made in bacterial or fungal (e.g., yeast) expression systems.
- recombinant microbial defines a protein produced in a microbial expression system which is essentially free of native endogenous substances. Protein expressed in most bacterial cultures, e.g., E. coli, will be free of glycan. Protein expressed in yeast
- 33 may have a glycosylation pattern different from that expressed in mammalian cells.
- Bioly active as used throughout the specification, e.g., as a characteristic of IL-4 receptors, means that a particular molecule shares sufficient amino acid sequence similarity with the embodiments of the present invention disclosed herein to be capable of binding detectable quantities of IL-4, transducing an IL-4 signal to a cell, for example, as a component of a hybrid receptor construct, or cross-reacting with anti-IL-4R antibodies raised against IL-4R from natural (i.e., nonrecombinant) sources.
- biologically active IL-4 receptors within the scope of the present invention are capable of binding greater than 0.1 nmoles IL-4 per nmole receptor, and most preferably, greater than 0.5 nmole IL-4 per nmole receptor in standard binding assays (see below).
- DNA sequence refers to a DNA molecule, in the form of a separate fragment or as a component of a larger DNA construct, which has been derived from DNA isolated at least once in substantially pure form, i.e., free of contaminating endogenous materials and in a quantity or concentration enabling identification, manipulation, and recovery of the sequence and its component nucleotide sequences by standard biochemical methods, for example, using a cloning vector.
- sequences are preferably provided in the form of an open reading frame uninterrupted by internal nontranslated sequences, or introns, which are typically present in eukaryotic genes. Genomic DNA containing the relevant sequences could also be used. Sequences of non-translated DNA may be present 5' or 3' from the open reading frame, where the same do not interfere with manipulation or expression of the coding regions.
- Nucleotide sequence refers to a heteropolymer of deoxyribonucleotides. DNA sequences encoding the proteins provided by this invention can be assembled from cDNA fragments and short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic gene which is capable of being expressed in a recombinant transcriptional unit.
- Recombinant expression vector refers to a replicable DNA construct used either to amplify or to express DNA which encodes IL-4R and which includes a transcriptional unit comprising an assembly of (1 ) a genetic element or elements having a regulatory role in gene expression, for example, promoters or enhancers, (2) a structural or coding sequence which is transcribed into mRNA and translated into
- Structural elements intended for use in yeast expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell.
- recombinant protein may include an N-terminal methionine residue. This residue may optionally be subsequently cleaved from the expressed recombinant protein to provide a final product.
- Recombinant microbial expression system means a substantially homogenous monoculture of suitable host micro-organisms, for example, bacteria such as E. coli or yeast such as S. cerevisiae, which have stably integrated a recombinant transcriptional unit into chromosomal DNA or carry the recombinant transcriptional unit as a component of a resident plasmid.
- suitable host micro-organisms for example, bacteria such as E. coli or yeast such as S. cerevisiae, which have stably integrated a recombinant transcriptional unit into chromosomal DNA or carry the recombinant transcriptional unit as a component of a resident plasmid.
- cells constituting the system are the progeny of a single ancestral transformant.
- Recombinant expression systems as defined herein will express heterologous protein upon induction of the regulatory elements linked to the DNA sequence or synthetic gene to be expressed.
- the present invention provides substantially homogeneous recombinant mammalian IL-4R polypeptides substantially free of contaminating endogenous materials and, optionally, without associated native-pattern glycosylation.
- the native murine and human IL-4 receptor molecules are recovered from cell lysates as glycoproteins having an apparent molecular weight by SDS-PAGE about 130-145 kilodaltons (kDa).
- Mammalian IL-4R of the present invention include, by way of example, primate, human, murine, canine, feline, bovine, ovine, equine and porcine IL- 4R.
- Derivatives of IL-4R within the scope of the invention also include various structural forms of the primary protein which retain biological activity. Due to the presence of ionisable amino and carboxyl groups, for example, an IL-4R protein may be in the form of acidic or basic salts, or in neutral form. Individual amino acid residues may also be modified by oxidation or reduction.
- the primary amino acid structure may be modified by forming covalent or aggregative conjugates with other chemical moieties, such as glycosyl groups, lipids, phosphate, acetyl groups and the like, or by creating amino acid sequence mutants.
- Covalent derivatives are prepared by linking particular functional groups to IL-4R amino acid side chains or at the N- or C-termini. Other derivatives of IL-4R within the scope
- the conjugated peptide may be a signal (or leader) polypeptide sequence at the N-terminal region of the protein which co- translationally or post-translationally directs transfer of the protein from its site of synthesis to its site of function inside or outside of the cell membrane or wall (e.g., the G-factor leader).
- IL-4R protein fusions can comprise peptides added to facilitate purification or identification of IL-4R (e.g., poly-His).
- poly-HIS fusion construct that is biologically active are soluble human IL-4R (1-207) His His and soluble human IL-4R (1-207) His His His His His His (SEQ ID NO. 3).
- the amino acid sequence of IL-4 receptor can also be linked to the peptide Asp-Tyr-Lys-Asp-Asp-Asp- Asp-Lys (DYKDDDDK) (SEQ ID NO. 4) (Hopp et al., Bio/Technology 6:1204, 1988)
- the latter sequence is highly antigenic and provides an epitope reversibly bound by a specific monoclonal antibody, enabling rapid assay and facile purification of expressed recombinant protein.
- This sequence is also specifically cleaved by bovine mucosal enterokinase at the residue immediately following the Asp-Lys pairing. Fusion proteins capped with this peptide may also be resistant to intracellular degradation in E. coli.
- a specific example of such a peptide is soluble human IL-4R (1-207) Asp Tyr Lys Asp Asp Asp Asp Lys (SEQ ID NO. 3).
- IL-4R derivatives may also be used as immunogens, reagents in receptor-based immunoassay, or as binding agents for affinity purification procedures of IL-4 or other binding ligands.
- IL-4R derivatives may also be obtained by cross-linking agents, such as M-maleimidobenzoyl succinimide ester and N-hydroxysuccinimide, at cysteine and lysine residues.
- IL-4R proteins may also be covalently bound through reactive side groups to various insoluble substrates, such as cyanogen bromide-activated, bisoxirane-activated, carbonyldiimidazole-activated or tosyl-activated agarose structures, or by adsorbing to polyolefin surfaces (with or without glutaraldehyde cross- linking).
- IL-4R may be used to selectively bind (for purposes of assay or purification) anti-IL-4R antibodies or IL-4.
- the present invention also includes IL-4R with or without associated native- pattern glycosylation.
- IL-4R expressed in yeast or mammalian expression systems, e.g., COS-7 cells, may be similar or significantly different in molecular weight and
- IL-4R DNAs in bacteda such as E. coli provides non- glycosylated molecules.
- Functional mutant analogs of mammalian IL-4R having inactivated N-glycosylation sites can be produced by obligonucleotide synthesis and ligation or by site-specific mutagenesis techniques. These analog proteins can be produced in a homogenous, reduced-carbohydrate form in good yield using yeast expression systems.
- N-glycosylation sites in eukaryotic proteins are characterised by the amino acid triplet Asn-A Z, where A ⁇ is any amino acid except Pro, and Z is Ser or Thr.
- asparagine profices a side chain amino group for covalent attachment of carbohydrate.
- Such a site can be eliminated by substituting another amino acid for Asn or for residue Z, deleting Asn or Z, or inserting a non-Z amino acid between A ⁇ and Z, or an amino acid other than Asn between Asn and A
- IL-4R derivatives may also be obtained by mutations of IL-4R or its subunits.
- An IL-4R mutant as referred to herein, is a polypeptide homologous to IL-4R but which has an amino acid sequence different from native IL-4R because of a deletion, insertion or substitution.
- mammalian IL-4 receptors are presumably encoded by multi-exon genes.
- Alternative mRNA constructs which can be attributed to different nRNA splicing events following transcription, and which share large regions of identity or similarity with the cDNAs claimed herein, are considered to be within the scope of the present invention.
- Bioequivalent analogs of IL-4R proteins may be constructed by, for example, making various substitutions of residues or sequences or deleting terminal or internal residues or sequences not needed for biological activity.
- cysteine residues can be deleted or replaced with other amino acids to prevent formation of incorrect intramolecular disulfide bridges upon renaturation.
- Other approaches to mutagenesis involve modification of adjacent diabasic amino acid residues to enhance expression in yeast systems in which KEX2 protease activity is present.
- substitutions should be made conservatively; i.e., the most preferred substitute amino acids are those having physiochemical characteristics resembling those of the residue to be replaced.
- the potential effect of the deletion or insertion on biological activity should be considered.
- Subunits of IL-4R may be constructed by deleting terminal or internal residues
- Particularly preferred subunits include those in which the transmembrane region and intracellular domain of IL-4R are deleted or substituted with hydrophilic residues to facilitate secretion of the receptor into the cell culture medium.
- the resulting protein is a soluble IL-4R molecule which may retain its ability to bind IL-4.
- Particular examples of soluble IL-4R include polypeptides having substantial identity to soluble murine IL-4R (1-208), soluble human IL-4R (1-207) and soluble human IL-4R (1-198), all of which retain the biological activity of soluble human IL-4R (1-207).
- Chimeric polypeptides comprising fragments of human and murine IL-4R may also be constructed, for example, IL-4R (1-197) Pro Ser Asn Glu Asn Leu (SEQ ID NO. 5), which is comprised of the sequence of amino acids 1-197 of human IL-4R followed by the N-terminal six amino acids of soluble murine IL-4R clone 18. This polypeptide has been found to retain the biological activity of soluble IL-4R (1-207).
- compositions including the peptide IL-4R the peptide is admixed with a pharmaceutically acceptable carrier or excipient which is preferably inert.
- a pharmaceutically acceptable carrier or excipient which is preferably inert.
- Preparation of such pharmaceutical compositions are known in the art: see, for example, Remington's Pharmaceutical Sciences and U.S. Pharmacopeia: National Formulary, Mack Publishing Company, Easton, Pa. (1984).
- the peptide may be administered in aqueous vehicles such as water, saline or buffered vehicles with or without various additives and/or diluting agents.
- a suspension such as a zinc suspension, can be prepared to include the peptide.
- Such a suspension can be useful for subcutaneous (SQ) or intramuscular (IM) injection.
- SQ subcutaneous
- IM intramuscular
- the proportion of peptide and additive can be varied over a broad range so long as both are present in effective amounts.
- the amount of the peptide can range from about 10 ⁇ g to about 1500 ⁇ g of each protein per kilogram body weight of the patients.
- a preferable range is from about 300 ⁇ g to about 800 ⁇ g.
- compositions may be ingested orally or injected into the body. Injections are usually intramuscular, subcutaneous, intradermal or intravenous. Alternatively, intra- articular injection or other routes could be used in appropriate circumstances. Additionally, compositions including the peptide IL-4R may be implanted into a patient or injected using a drug delivery system. See, for example, Urquhart, et al., Ann. Rev.
- the peptide is administered parenterally and preferably in a unit dosage injectable form.
- injectable form examples include solutions, suspensions and emulsions.
- the peptide is injected in association with a pharmaceutical carrier such as normal saline, Ringer's solution, dextrose solution and other aqueous carriers known in the art.
- a pharmaceutical carrier such as normal saline, Ringer's solution, dextrose solution and other aqueous carriers known in the art.
- Appropriate non-aqueous carriers may also be used and examples include fixed oils and ethyl oleate.
- a preferred carrier is 5% dextrose in saline.
- additives in the carrier such as buffers and preservatives or other substances to enhance isotonicity and chemical stability.
- the peptide, IL-4R is formulated in purified form substantially free of aggregates and other proteins at a concentration of about 1 to 30 mg/ml.
- concentration of the peptide in a unit dose is from about 60 micrograms to 200 milligrams varying with the application and the potency of the peptide.
- IL-4R may be administered by any of a number of routes, an intravenous infusion or bolus is preferred. Most preferably, an intravenous injection delivers about 1 mg to about 100 mg of the peptide per day.
- the dose range is about 15 ⁇ g to 1500 ⁇ g per kilogram of body weight of the recipient per day per peptide. Dosages should be varied according to side effects and blood cell counts which should be monitored frequently, preferably daily.
- the agonist and antagonists are preferably administered intravenously.
- a preferred antagonist is an antibody specific for binding to IL-4.
- the antibodies can be chimeric, recombinant, polyclonal or monoclonal. Autologous antibodies, human or humanized antibodies are preferred for safety when human patients are being treated.
- the preferred single dosage of antibodies is 1-10 mg/kg body weight per antibody. Alternatively, the amount of the antibody administered in a single dose is about 10 to about 100 ⁇ g per milliliter of patient sera.
- an effective amount for a particular patient may vary depending on factors such as the condition being treated, the overall health of the patient, the method route and dose of administration and the severity of side effects. Determination of the appropriate dose is made by the clinician using parameters known in the art. Generally, the dose
- the total daily dose of the peptide can be given as bolus injection, such as an intravenous injection, or it can be given as a continuous infusion. Alternatively, the daily dosage may be divided into several smaller doses for multiple bolus intravenous administration. Other routes of administration such as intramuscular injection, can be employed.
- a method which comprises co- administering to the mammal an effective amount of each of agonist or antagonist to IL-4 and one or more anti-viral agents.
- the mammal is preferably a human.
- the co- administering can be simultaneous or sequential.
- "co-administering" means that the cytokine is present in the recipient during a specified time interval.
- the anti-viral agent is administered within the half life of the cytokine.
- the co-administration is parenteral, and most preferably it is intravenous.
- the effective amount is selected from a range from about 15 ⁇ g to about 1500 ⁇ g per kilogram of body weight of the mammal.
- Mutations in nucleotide sequences constructed for expression of analog IL-4Rs must, of course, preserve the reading frame phase of the coding sequences and preferably will not create complementary regions that could hybridise to produce secondary mRNA structures, such as loops or hairpins, which would adversely affect translation of the receptor mRNA.
- a mutation site may be predetermined, it is not necessary that the nature of the mutation per se be predetermined. For example, in order to select for optimum characteristics of mutants at a given site, random mutagenesis may be conducted at the target codon and the expressed IL-4R mutants screened for the desired activity.
- This invention includes (among others) treatments against viral, bacterial, and mycoplasma infections by any suitable route including enteric, parenteral, topical, oral, rectal, nasal or vaginal routes.
- Parenteral routes include subcutaneous, intramuscular, intravenous and sublingual administration.
- the preferred route of administration would be an intravenous one but this may not be feasible with a large patient base and oral administration of compounds may be the most preferred route.
- the Antagonists are preferably administered intravenously.
- the 40 antagonist is an antibody specific for binding to IL-4.
- the antibodies can be chimeric, recombinant, polyclonal or monoclonal. Autologous antibodies, human or humanized antibodies are preferred for safety when human patients are being treated.
- the preferred single dosage of antibodies is 1-10 mg/kg body weight per antibody. Alternatively, the amount of the antibody administered in a single dose is about 10 to about I00 ⁇ g per milliliter of patient sera.
- the patient was HIV+ and had been taking a combination course of both reverse transcriptase inhibitors combined with Protease inhibitors. His viral load had decreased initially upon the commencement of the Protease and Reverse transcriptase inhibitors combination therapy regime. However, his CD4 absolute and percentage values did not show any improvement with this conventional therapy. See Figs. 3A, 3B, 3C and 3D wherein the patient was monitored over a period of 208 days during which he was receiving various therapies as per the present invention. Treatment A, herein the patient stopped all his standard therapy and was administered Anti-serum to IL-10 (Recombinant Human). During this period viral reproduction was observed. Over a period of 14 days, the HIV-I RNA g PCR rose from 15,384 to 157,812.
- the bloodwork analysis obtained by the administration of a Th 2 cytokine antibody alone (no anti viral treatment) is contrary to the teaching of International Publication Number WO 94/06473.
- the patient was maintained on his original conventional (Protease and Reverse transcriptase inhibitors) therapy but he was also co-administered rabbit generated polyclonal Antiserum to human Interleukin 10 and human Interleukin 4, treatment B Figs. 3A, 3B, 3C and 3D.
- the antibody class was IgG and the respective antigens were recombinant human IL-10 and recombinant human IL-4 (see Tables A and B, below).
- IL-1-beta IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-11 , IL-15, EGF, FGFa, FGFb, GM-CSF, GRO-alpha, IGF-1 , IGF-11 , IFN-alpha, IFN-gamma, MIP-1-alpha, MIP- 1-beta, MCAF, MCP-2, MCP-3,PDGF-aa, RANTES, TGF-alpha, TNF-alpha, TNF-beta, TPO, VEGF, murine IL-1-alpha, murine IL-1-beta, and IgG done by EIA.
- PRODUCT FORM Liquid RECOMMENDED DILUENT: Tris Buffered Saline
- CROSS-REACTIVITY No cross reactivity with WHO standards: IL-1-alpha, IL-1-beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-11 , IL-13, IL-
- the dosage used was 2 mg/ml of each antibody and 2 mis was administered IV every day for seven days.
- the results were that viral load as measured by PCR decreased by one log the first week of the injections and to undetectable levels by the following week (14 days ⁇ 400 copies).
- the Helper T (CD4) absolute and percentage readings changed from 177 (wk. 0) to 276 (wk. 1) and from 11% (wk.0) to 15% (wk. I).
- suppresser T(CD8) percentage 73% (wk.0) to 67% (wk.1).
- the patient experienced some flu-like symptoms immediately following the injections but no toxicity or discomfort were reported for this therapy.
- the patient showed a rapid development of anti-rabbit antibodies and further therapy required the
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU15797/00A AU1579700A (en) | 1998-12-15 | 1999-12-15 | Cytokine combination therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11220698P | 1998-12-15 | 1998-12-15 | |
US60/112,206 | 1998-12-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000035472A2 true WO2000035472A2 (en) | 2000-06-22 |
WO2000035472A3 WO2000035472A3 (en) | 2000-11-09 |
Family
ID=22342651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB1999/002001 WO2000035472A2 (en) | 1998-12-15 | 1999-12-15 | Cytokine combination therapy |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU1579700A (en) |
WO (1) | WO2000035472A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7553932B1 (en) | 2005-04-25 | 2009-06-30 | La Jolla Institute For Allergy And Immunology | Methods of treating viral infection with IL-10 receptor antagonists |
US7589184B2 (en) | 2004-05-24 | 2009-09-15 | Genvault Corporation | Stable protein storage and stable nucleic acid storage in recoverable form |
US8283165B2 (en) | 2008-09-12 | 2012-10-09 | Genvault Corporation | Matrices and media for storage and stabilization of biomolecules |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998010787A2 (en) * | 1996-09-11 | 1998-03-19 | Prendergast Patrick T | Pharmaceutical compositions for the treatment of immune disorders |
WO1998047516A1 (en) * | 1997-04-17 | 1998-10-29 | Prendergast Patrick T | Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors |
WO2000009150A2 (en) * | 1998-08-17 | 2000-02-24 | Prendergast Patrick T | Cytokine and cytokine receptor, agonist, antagonist and/or antibody combination for therapeutic use |
-
1999
- 1999-12-15 AU AU15797/00A patent/AU1579700A/en not_active Abandoned
- 1999-12-15 WO PCT/IB1999/002001 patent/WO2000035472A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998010787A2 (en) * | 1996-09-11 | 1998-03-19 | Prendergast Patrick T | Pharmaceutical compositions for the treatment of immune disorders |
WO1998047516A1 (en) * | 1997-04-17 | 1998-10-29 | Prendergast Patrick T | Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors |
WO2000009150A2 (en) * | 1998-08-17 | 2000-02-24 | Prendergast Patrick T | Cytokine and cytokine receptor, agonist, antagonist and/or antibody combination for therapeutic use |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7589184B2 (en) | 2004-05-24 | 2009-09-15 | Genvault Corporation | Stable protein storage and stable nucleic acid storage in recoverable form |
US7553932B1 (en) | 2005-04-25 | 2009-06-30 | La Jolla Institute For Allergy And Immunology | Methods of treating viral infection with IL-10 receptor antagonists |
US8283165B2 (en) | 2008-09-12 | 2012-10-09 | Genvault Corporation | Matrices and media for storage and stabilization of biomolecules |
US8951719B2 (en) | 2008-09-12 | 2015-02-10 | Gentegra, LLC. | Matrices and media for storage and stabilization of biomolecules |
US9637513B2 (en) | 2008-09-12 | 2017-05-02 | Gentegra Llc | Matrices and media for storage and stabilization of biomolecules |
US10160997B2 (en) | 2008-09-12 | 2018-12-25 | Gentegra Llc | Matrices and media for storage and stabilization of biomolecules |
Also Published As
Publication number | Publication date |
---|---|
AU1579700A (en) | 2000-07-03 |
WO2000035472A3 (en) | 2000-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3825467B2 (en) | Selected immunotherapy with interleukin-7 | |
KR970005050B1 (en) | A mammalian cytokine il-11 | |
US5985262A (en) | Method of treatment with epithelium derived T-cell factor | |
SK8396A3 (en) | Antagonists and agonists of human interleukin-10 | |
EP0832132B1 (en) | Lymphocyte chemoattractant factor and uses thereof | |
JP2006182783A (en) | Lymphocyte chemical inducible factor and its use | |
JP3657271B2 (en) | Composition for the treatment of mammals infected with pathogenic or opportunistic infectious organisms | |
KR20080052690A (en) | Mutant human cd80 and compositions for and methods of making and using the same | |
KR101636139B1 (en) | Mesenchymal stem cells overexpressing sRAGE and cell therapeutic agent for preventing or treating immune disease | |
Stein et al. | Immune-based therapeutics: scientific rationale and the promising approaches to the treatment of the human immunodeficiency virus-infected individual | |
EP0630257B1 (en) | Thymus-derived, immune-enhancing agent for therapeutic use in immunocompromised hosts | |
Lehner et al. | Induction of inhibitory antibodies to the CCR5 chemokine receptor and their complementary role in preventing SIV infection in macaques | |
US20150018274A1 (en) | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators | |
WO2000035472A2 (en) | Cytokine combination therapy | |
JP3875730B2 (en) | Preventive and therapeutic agent for autoimmune diseases | |
WO2000009150A2 (en) | Cytokine and cytokine receptor, agonist, antagonist and/or antibody combination for therapeutic use | |
US6106823A (en) | Treatment of neoplastic disease with interleukin-10 | |
JP2000515007A (en) | T cell selective interleukin-4 agonist | |
US6410009B1 (en) | Pharmaceutical composition for treating hepatitis B virus (HBV) infection | |
EP3307298B1 (en) | Multi-peptide composition | |
CA2228379A1 (en) | Combined use of interleukin-10 and cyclosporin for immunosuppression therapy | |
JPH05117163A (en) | Medicinal preparation for maturation of prothymocyte | |
KR20000005539A (en) | Dhea combination therapy | |
US6921530B1 (en) | Low dose IL-2 for potentiation of immunity | |
US20040116344A1 (en) | Immunomodulatory properties of bip |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase in: |
Ref country code: AU Ref document number: 2000 15797 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |